The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
Open accessAbstract
BACKGROUND: Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In phase 2 studies involving patients with chronic kidney disease, roxadustat increased levels of endogenous erythropoietin to within or near the physiologic range, along with increasing hemoglobin levels and improving iron homeostasis. Additional data are needed regarding the efficacy and safety of roxadustat for the treatment of anemia in patients with chronic kidney disease who are not undergoing dialysis. METHODS: In this phase 3 trial conducted at 29 sites in China, we randomly assigned 154 patients with chronic kidney disease in a 2:1 ratio to receive roxadustat or placebo three times a week for 8 weeks in a double-blind manner. All the patients had a hemoglobin level of 7.0 to 10.0 g per deciliter at baseline. The randomized phase of the trial was followed by an 18-week open-label period in which all the patients received roxadustat; parenteral iron was withheld. The primary end point was the mean change from baseline in the hemoglobin level, averaged over weeks 7 through 9. RESULTS: During the primary-analysis period, the mean (±SD) change from baseline in the hemoglobin level was an increase of 1.9±1.2 g per deciliter in the roxadustat group and a decrease of 0.4±0.8 g per deciliter in the placebo group (P<0.001). The mean reduction from baseline in the hepcidin level (associated with greater iron availability) was 56.14±63.40 ng per milliliter in the roxadustat group and 15.10±48.06 ng per milliliter in the placebo group. The reduction from baseline in the total cholesterol level was 40.6 mg per deciliter in the roxadustat group and 7.7 mg per deciliter in the placebo group. Hyperkalemia and metabolic acidosis occurred more frequently in the roxadustat group than in the placebo group. The efficacy of roxadustat in hemoglobin correction and maintenance was maintained during the 18-week open-label period. CONCLUSIONS: In Chinese patients with chronic kidney disease who were not undergoing dialysis, those in the roxadustat group had a higher mean hemoglobin level than those in the placebo group after 8 weeks. During the 18-week open-label phase of the trial, roxadustat was associated with continued efficacy. (Funded by FibroGen and FibroGen [China] Medical Technology Development; ClinicalTrials.gov number, NCT02652819.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prolyl hydroxylase inhibitors or HIF stabilizers, now tested in chronic kidney disease, by increasing HIF-2α might target two abnormal processes enhancing both erythropoietin synthesis and iron absorption.134”
From Iron metabolism and iron disorders revisited in the hepcidin era (2020) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895
Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Self-citationPrevalence of chronic kidney disease in China: a cross-sectional survey
Zhang, L., Wang, F., Wang, L., Wang, W., Liu, B., Liu, J., Chen, M., He, Q., Liao, Y., Yu, X., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60033-6 · Cited by 2,104
Self-citationA trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,094
Ganz, T., & Nemeth, E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.014 · Cited by 1,282
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Regulation of Iron Metabolism by Hepcidin
Nemeth, E., & Ganz, T. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111303 · Cited by 756
Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)
Peyssonnaux, C., Zinkernagel, A. S., Schuepbach, R. A., Rankin, E., Vaulont, S., Haase, V. H., Nizet, V., & Johnson, R. S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31370 · Cited by 639
Research works printed but not linked: 3
- Zhu LN, Lv W, Teng J, et al. Association of residual renal function at initiation of dialysis with prognosis in maintenance dialysis patients. Chin J Nephrol 2012:757-764.
- Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant 2003;18:Suppl 2:ii2-ii6.12819293
- KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3(1):1-150 (https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf).
Cited by
Sorted by citations
Regulation of glycolysis by the hypoxia-inducible factor (HIF): Implications for cellular physiology
Kierans, S. J., & Taylor, C. T. (2021) · The Journal of Physiology · doi:10.1113/jp280572 · Cited by 1,015
Iron metabolism and iron disorders revisited in the hepcidin era
Camaschella, C., Nai, A., & Silvestri, L. (2020) · Haematologica · doi:10.3324/haematol.2019.232124 · Cited by 734
Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis
Chen, N., Hao, C., Liu, B., Lin, H., Wang, C., Xing, C., Liang, X., Jiang, G., Liu, Z., Li, X., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901713 · Cited by 630
Self-citationHypoxia signaling in human health and diseases: implications and prospects for therapeutics
Luo, Z., Tian, M., Yang, G., Tan, Q., Chen, Y., Li, G., Zhang, Q., Li, Y., Wan, P., & Wu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01080-1 · Cited by 499
Lin, Q., Li, S., Jiang, N., Jin, H., Shao, X., Zhu, X., Wu, J., Zhang, M., Zhang, Z., Shen, J., et al. (2020) · Autophagy · doi:10.1080/15548627.2020.1848971 · Cited by 397
Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents
Portolés, J. M., Martín-Rodriguez, L., Broseta, J. J., & Cases, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.642296 · Cited by 417
Zoccali, C., Mallamaci, F., Adamczak, M., de Oliveira, R. B., Massy, Z. A., Sarafidis, P. A., Agarwal, R., Mark, P. B., Kotanko, P., Ferro, C. J., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad083 · Cited by 399
Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment
Batchelor, E. K., Kapitsinou, P. P., Pérgola, P. E., Kovesdy, C. P., & Jalal, D. I. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019020213 · Cited by 349
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges
Yuan, X., Ruan, W., Bobrow, B., Carmeliet, P., & Eltzschig, H. K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00848-6 · Cited by 245
2-Oxoglutarate-dependent dioxygenases in cancer
Losman, J.-A., Koivunen, P., & Kaelin, W. G. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-00303-3 · Cited by 241
Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin
Hanna, R. M., Streja, E., & Kalantar‐Zadeh, K. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01524-6 · Cited by 235
Packer, M. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.04.016 · Cited by 218
Babitt, J. L., Eisenga, M. F., Haase, V. H., Kshirsagar, A. V., Levin, A., Locatelli, F., Małyszko, J., Swinkels, D. W., Tarng, D., Cheung, M., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.020 · Cited by 222
Self-citationSignaling Pathways Involved in Diabetic Renal Fibrosis
Zhang, Y., Jin, D., Kang, X., Zhou, R., Sun, Y., Lian, F., & Tong, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.696542 · Cited by 222
Hesp, A. C., Schaub, J. A., Prasad, P. V., Vallon, V., Laverman, G. D., Bjornstad, P., & van Raalte, D. H. (2020) · Kidney International · doi:10.1016/j.kint.2020.02.041 · Cited by 202
Haase, V. H. (2021) · Kidney International Supplements · doi:10.1016/j.kisu.2020.12.002 · Cited by 205
Fishbane, S. N., El-Shahawy, M. A., Pecoits‐Filho, R., Van, B. P., Houser, M. T., Frison, L., Little, D. J., Guzman, N. J., & Pérgola, P. E. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020081150 · Cited by 193
The Influence of Inflammation on Anemia in CKD Patients
Gluba-Brzózka, A., Franczyk, B., Olszewski, R., & Rysz, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030725 · Cited by 192
Hypoxia and chronic kidney disease
Wang, B., Li, Z., Zhang, Y., Wen, Y., Gao, Y.-M., & Liu, B. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103942 · Cited by 181
Self-citationAcyl Radicals from α-Keto Acids: Metal-Free Visible-Light-Promoted Acylation of Heterocycles
Zhu, H.-L., Zeng, F., Chen, X., Sun, K., Li, H., Yuan, X., Qu, L., & Yu, B. (2021) · Organic Letters · doi:10.1021/acs.orglett.1c00655 · Cited by 169
Lanser, L., Fuchs, D., Kurz, K., & Weiß, G. (2021) · Nutrients · doi:10.3390/nu13113732 · Cited by 179
Zhang, X., Zhang, Y., Wang, P., Zhang, S., Dong, Y., Zeng, G., Yan, Y., Sun, L., Wu, Q., Liu, H., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.016 · Cited by 154
Self-citationBarratt, J., Andrić, B., Tataradze, A., Schömig, M., Reusch, M., Valluri, U., & Mariat, C. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab191 · Cited by 157
Ku, E., Vecchio, L. D., Eckardt, K., Haase, V. H., Johansen, K. L., Nangaku, M., Tangri, N., Waikar, S. S., Więcek, A., Cheung, M., et al. (2023) · Kidney International · doi:10.1016/j.kint.2023.05.009 · Cited by 162
Self-citationRoxadustat for anemia in patients with end-stage renal disease incident to dialysis
Provenzano, R., Shutov, E. V., Еремеева, Л. Ф., Korneyeva, S., Poole, L., Saha, G. C., Bradley, C., Eyassu, M., Besarab, A., Leong, R., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab051 · Cited by 140
Self-citationOshima, M., Neuen, B. L., Jardine, M. J., Bakris, G., Edwards, R., Levin, A., Mahaffey, K. W., Neal, B., Pollock, C., Rosenthal, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30300-4 · Cited by 135
Querfeld, U., MAK, R. H. K., & Pries, A. R. (2020) · Clinical Science · doi:10.1042/cs20200279 · Cited by 136
The roles of HIF-1α signaling in cardiovascular diseases
Sato, T., & Takeda, N. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.09.002 · Cited by 135
Shutov, E. V., Sułowicz, W., Esposito, C., Tataradze, A., Andrić, B., Reusch, M., Valluri, U., & Dimkovic, N. B. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab057 · Cited by 126
How I treat cancer-associated anemia
Gilreath, J. A., & Rodgers, G. M. (2020) · Blood · doi:10.1182/blood.2019004017 · Cited by 126
Roxadustat for CKD-related Anemia in Non-dialysis Patients
Coyne, D. W., Roger, S. D., Shin, S. K., Kim, S. G., Cadena, A., Moustafa, M. A., Chan, T. M., Besarab, A., Chou, W., Bradley, C., et al. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.11.034 · Cited by 126
Self-citationRetractedHIF-α Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review
Hirota, K. (2021) · Biomedicines · doi:10.3390/biomedicines9050468 · Cited by 115
Csiky, B. S., Schömig, M., Esposito, C., Barratt, J., Reusch, M., Valluri, U., & Sułowicz, W. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01904-6 · Cited by 116
Hypoxic and Pharmacological Activation of HIF Inhibits SARS-CoV-2 Infection of Lung Epithelial Cells
Wing, P. A. C., Keeley, T. P., Zhuang, X., Lee, Y. S., Prange‐Barczynska, M., Tsukuda, S., Morgan, S. B., Harding, A. C., Argles, I. L. A., Kurlekar, S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2021.109020 · Cited by 108
Badura, K., Janc, J. J., Wąsik, J., Gnitecki, S., Skwira, S., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · Biomedicines · doi:10.3390/biomedicines12061191 · Cited by 106
Yap, D. Y. H., McMahon, L. P., Hao, C., Hu, N., Okada, H., Suzuki, Y., Kim, S. G., Lim, S. K., Vareesangthip, K., Hung, C., et al. (2020) · Nephrology · doi:10.1111/nep.13835 · Cited by 106
Self-citationMolecular and cellular mechanisms that regulate human erythropoiesis
Caulier, A., & Sankaran, V. G. (2021) · Blood · doi:10.1182/blood.2021011044 · Cited by 113
A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study
Charytan, C., Manllo-Karim, R., Martin, E. R., Steer, D. L., Bernardo, M. V., Dua, S., Moustafa, M. A., Saha, G. C., Bradley, C., Eyassu, M., et al. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.04.007 · Cited by 106
Self-citationWeir, M. R. (2021) · American Journal of Nephrology · doi:10.1159/000516901 · Cited by 101
Provenzano, R., Szczech, L. A. M., Leong, R., Saikali, K. G., Zhong, M., Lee, T. T., Little, D. J., Houser, M. T., Frison, L., Houghton, J., et al. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.16191020 · Cited by 95
Self-citationXu, Y., Alfaro-Magallanes, V. M., & Babitt, J. L. (2020) · British Journal of Haematology · doi:10.1111/bjh.17252 · Cited by 99
Peritubular Capillary Rarefaction: An Underappreciated Regulator of CKD Progression
Kida, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218255 · Cited by 93
Molecular medicinal insights into scaffold hopping-based drug discovery success
Acharya, A., Yadav, M., Nagpure, M., Kumaresan, S., & Guchhait, S. K. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103845 · Cited by 88
Treatment of Renal Anemia with Roxadustat: Advantages and Achievement
Li, Z., Tu, Y., & Liu, B. (2020) · Kidney Diseases · doi:10.1159/000504850 · Cited by 83
Self-citationNangaku, M., Kondo, K., Kokado, Y., Ueta, K., Kaneko, G., Tandai, T., Kawaguchi, Y., & Komatsu, Y. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020091311 · Cited by 85
Chen, H., Cheng, Q., Wang, J., Zhao, X., & Zhu, S. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13385 · Cited by 80
The role of CD71+ erythroid cells in the regulation of the immune response
Grzywa, T. M., Nowis, D., & Gołąb, J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107927 · Cited by 81
Barratt, J., Sułowicz, W., Schömig, M., Esposito, C., Reusch, M., Young, J., & Csiky, B. S. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01903-7 · Cited by 83
KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)
Tonelli, M. A., Berns, J. B., Bozkurt, B., Cheung, R., Cuevas, Y., Effa, E. E., Eisenga, M. F., Fishbane, S., Ginzburg, Y. Z., Haase, V. H., et al. (2026) · Kidney International · doi:10.1016/j.kint.2025.06.006 · Cited by 99
Uremic Toxins Affect Erythropoiesis during the Course of Chronic Kidney Disease: A Review
Hamza, E., Metzinger, L., & Meuth, V. M. (2020) · Cells · doi:10.3390/cells9092039 · Cited by 77
Turning the Oxygen Dial: Balancing the Highs and Lows
Baik, A. H., & Jain, I. H. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.04.005 · Cited by 70
Zheng, Q., Yang, H., Sun, L., Wei, R., Fu, X., Wang, Y., Huang, Y., Liu, Y., & Liu, W. J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105020 · Cited by 77
Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD
Akizawa, T., Iwasaki, M., Otsuka, T., Yamaguchi, Y., & Reusch, M. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.04.003 · Cited by 74
Semenza, G. L. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-102602 · Cited by 74
Activation of γ-globin expression by hypoxia-inducible factor 1α
Feng, R., Mayuranathan, T., Huang, P., Doerfler, P. A., Li, Y., Yao, Y., Zhang, J., Palmer, L. E., Mayberry, K. D., Christakopoulos, G. E., et al. (2022) · Nature · doi:10.1038/s41586-022-05312-w · Cited by 69
Zheng, X., Narayanan, S., Xu, C., Angelstig, S. E., Grünler, J., Zhao, A., Toro, A. D., Bernardi, L., Mazzone, M., Carmeliet, P., et al. (2022) · eLife · doi:10.7554/elife.70714 · Cited by 69
del Balzo, U., Signore, P. E., Walkinshaw, G., Seeley, T. W., Brenner, M. C., Wang, Q., Guo, G., Arend, M., Flippin, L. A., Chow, F. A., et al. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.265181 · Cited by 71
Self-citationMitochondrial Dysfunction in Kidney Disease and Uremic Sarcopenia
Takemura, K., Nishi, H., & Inagi, R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.565023 · Cited by 68
How oxygenation shapes immune responses: emerging roles for physioxia and pathological hypoxia
Mirchandani, A. S., Sánchez-García, M. A., & Walmsley, S. R. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01087-5 · Cited by 77
Nangaku, M., Hamano, T., Akizawa, T., Tsubakihara, Y., Nagai, R., Okuda, N., Kurata, K., Nagakubo, T., Jones, N. P., Endo, Y., et al. (2021) · American Journal of Nephrology · doi:10.1159/000513103 · Cited by 66
Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial
Hou, Y., Mao, X.-Y., Wang, C., Xu, Z., Bu, Z.-H., Xu, M., & Li, B. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.06.004 · Cited by 67
Self-citationAkizawa, T., Ueno, M., Shiga, T., & Reusch, M. (2019) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13468 · Cited by 64
Disease Mechanisms of Perioperative Organ Injury
Conrad, C., & Eltzschig, H. K. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005191 · Cited by 63
Therapeutic Advances in Regulating the Hepcidin/Ferroportin Axis
Hawula, Z. J., Wallace, D. F., Subramaniam, V. N., & Rishi, G. (2019) · Pharmaceuticals · doi:10.3390/ph12040170 · Cited by 62
Mima, A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174583 · Cited by 63
Akizawa, T., Yamaguchi, Y., Otsuka, T., & Reusch, M. (2020) · The Nephron journals/Nephron journals · doi:10.1159/000508100 · Cited by 61
Stoumpos, S., Crowe, K., Sarafidis, P. A., Barratt, J., Bolignano, D., Vecchio, L. D., Małyszko, J., Więcek, A., Ortíz, A., & Cozzolino, M. G. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae075 · Cited by 70
Understanding the Oxygen-Sensing Pathway and Its Therapeutic Implications in Diseases
Liao, C., & Zhang, Q. H. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.04.003 · Cited by 64
Adenosine at the Interphase of Hypoxia and Inflammation in Lung Injury
Li, X., Berg, N. K., Mills, T., Zhang, K., Eltzschig, H. K., & Yuan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.604944 · Cited by 59
AUVINEN, J. P., Tapio, J., Karhunen, V., Kettunen, J., Serpi, R., Dimova, E. Y., Gill, D., Soininen, P., Tammelin, T., Mykkänen, J., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi4822 · Cited by 64
Reactive Oxygen Species and Nrf2: Functional and Transcriptional Regulators of Hematopoiesis
Hu, L., Zhang, Y., Miao, W., & Cheng, T. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/5153268 · Cited by 61
Henry, D. H., Glaspy, J. A., Harrup, R. A., Mittelman, M., Zhou, A. W., Carraway, H. E., Bradley, C., Saha, G. C., Modelska, K., Bartels, P., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26397 · Cited by 58
Self-citationStabilizing HIF to Ameliorate Anemia
Voit, R. A., & Sankaran, V. G. (2020) · Cell · doi:10.1016/j.cell.2019.12.010 · Cited by 58
Chronic kidney disease in children: an update
Cirillo, L., Chiara, L. D., Innocenti, S., Errichiello, C., Romagnani, P., & Becherucci, F. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad097 · Cited by 69
Fandrey, J., Schödel, J., Eckardt, K., Katschinski, D. M., & Wenger, R. H. (2019) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-019-02334-8 · Cited by 54
Iron metabolism and management: focus on chronic kidney disease
Agarwal, A. K. (2021) · Kidney International Supplements · doi:10.1016/j.kisu.2020.12.003 · Cited by 57
Roxadustat: Not just for anemia
Zhu, X., Jiang, L., Wei, X. S., Long, M., & Du, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.971795 · Cited by 64
Oxygen levels at the time of activation determine T cell persistence and immunotherapeutic efficacy
Cunha, P. P., Minogue, E., Krause, L. C. M., Hess, R. M., Bargiela, D., Wadsworth, B. J., Barbieri, L., Brombach, C., Foskolou, I. P., Bogeski, I., et al. (2023) · eLife · doi:10.7554/elife.84280 · Cited by 54
Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS
Yu, J., Wang, S., Shi, W., Zhou, W., Niu, Y., Huang, S., Zhang, Y., Zhang, A., & Jia, Z. (2021) · JCI Insight · doi:10.1172/jci.insight.133690 · Cited by 52
Locatelli, F., Minutolo, R., Nicola, L. D., & Vecchio, L. D. (2022) · Drugs · doi:10.1007/s40265-022-01783-3 · Cited by 53
Anaemia in CKD—treatment standard
Macdougall, I. C. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad250 · Cited by 64
Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease
Natale, P., Palmer, S. C., Jauré, A., Hodson, E. M., Ruospo, M., Cooper, T. E., Hahn, D., Saglimbene, V. M., Craig, J. C., & Strippoli, G. F. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013751.pub2 · Cited by 50
Sugahara, M., Tanaka, T., & Nangaku, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108272 · Cited by 52
Hirota, K. (2020) · Biomedicines · doi:10.3390/biomedicines8020032 · Cited by 52
Wu, M., Chen, W., Miao, M., Jin, Q., Zhang, S., Bai, M., Fan, J., Zhang, Y., Zhang, A., Jia, Z., et al. (2021) · Clinical Science · doi:10.1042/cs20210100 · Cited by 47
UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease
Bhandari, S., Spencer, S., Oliveira, B., Mikhail, A. I., Brooks, O., Bryant, G., Willicombe, M. K., Baines, R. J., Alldridge, L. C., & Haslam-England, S. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04115-1 · Cited by 51
Anemia: Perioperative Risk and Treatment Opportunity
Hare, G. M. T., & Mazer, C. D. (2021) · Anesthesiology · doi:10.1097/aln.0000000000003870 · Cited by 45
Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat
Czock, D., & Keller, F. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01095-x · Cited by 45
Erythropoietin-Stimulating Agent Hyporesponsiveness in Patients Living with Chronic Kidney Disease
Wu, H. H. L., & Chinnadurai, R. (2022) · Kidney Diseases · doi:10.1159/000521162 · Cited by 49
Liu, J., Zhang, A., Hayden, J. C., Bhagavathula, A. S., Alshehhi, F., Rinaldi, G., Kontogiannis, V., & Rahmani, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104747 · Cited by 45
Role of oxygen and the HIF-pathway in polycystic kidney disease
Buchholz, B., & Eckardt, K. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109524 · Cited by 46
Su, K., Li, Z., Yu, Y.-C., & Zhang, X. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.04.017 · Cited by 42
Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
Li, J., Haase, V. H., & Hao, C. (2022) · Kidney Diseases · doi:10.1159/000527835 · Cited by 42
Self-citationTo breathe or not to breathe: Understanding how oxygen sensing contributes to age-related phenotypes
van Vliet, T., Casciaro, F., & Demaria, M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101267 · Cited by 41
van Kuijk, K., Demandt, J. A. F., Perales-Patón, J., Theelen, T. L., Kuppe, C., Marsch, E., de Bruijn, J., Jin, H., Gijbels, M. J., Matic, L. P., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab152 · Cited by 40
Li, F., Wei, R., Huang, M., Chen, J., Li, P., Ma, Y., & Chen, X. (2022) · Food & Function · doi:10.1039/d2fo02477b · Cited by 41
Self-citationIacobini, C., Vitale, M., Haxhi, J., Pesce, C. M., Pugliese, G., & Menini, S. (2022) · Antioxidants · doi:10.3390/antiox11112183 · Cited by 43
Chronodisruption: A Poorly Recognized Feature of CKD
Carriazo, S. M., Ramos, A. M., Sanz, A. B., Sánchez-Niño, M. D., Kanbay, M., & Ortíz, A. (2020) · Toxins · doi:10.3390/toxins12030151 · Cited by 40
Yan, Z., & Xu, G. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00393 · Cited by 40
Coyne, D. W., Singh, A. K., Lópes, R. D., Bailey, C. K., Dimino, T. L., Huang, C., Connaire, J. J., Rastogi, A., Kim, S.-G., Orías, M., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00550122 · Cited by 43
Metadata
- Authors
- Chen, N., Hao, C., Peng, X., Lin, H., Yin, A., Hao, L., Tao, Y., Liang, X., Liu, Z., Xing, C., Chen, J., Luo, L., Zuo, L., Liao, Y., Liu, B.-C., Leong, R., Wang, C., Liu, C., Neff, T., Szczech, L., & Yu, K.-H. P.
- Affiliations
- Shanghai Jiao Tong University (CN)
- From the Department of Nephrology, Institute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (N.C.), and the Division of Nephrology, Huashan Hospital Fudan University (C.H.), Shanghai, the Department of Nephrology, People’s Hospital of Guangxi Zhuang Autonomous Region (X.P.), and the Department of Nephrology, First Affiliated Hospital of Guangxi Medical University (Y.L.), Nanning, the First Affiliated Hospital of Dalian Medical University, Dalian (H.L.), the...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-09-12
- Volume
- 381
- Issue
- 11
- Pages
- 1001-1010
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2963534431
- Cited by
- 582
- References
- 32
- Citations by year
- 2026: 53 · 2025: 62 · 2024: 68 · 2023: 68 · 2022: 96 · 2021: 112 · 2020: 100 · 2019: 22
- FWCI
- 58.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- FibroGen
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Keywords
- roxadustat, chronic kidney disease, anemia of chronic kidney disease, HIF prolyl hydroxylase inhibitors, non-dialysis patients, hemoglobin increase, hepcidin, iron metabolism, erythropoiesis, hyperkalemia, metabolic acidosis, total cholesterol, Chinese patients, open-label extension
- MeSH terms
- Acidosis, Adult, Aged, Anemia, Cholesterol, Double-Blind Method, Female, Glycine, Hematinics, Hemoglobins, Humans, Hyperkalemia, Isoquinolines, Male, Middle Aged, Renal Insufficiency, Chronic, Hypoxia-Inducible Factor-Proline Dioxygenases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
